JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.

Esketamine in Treatment-Resistant Depression: Clinical and Translational Perspectives.

Curr Neuropharmacol July 22, 2026 DOI: 10.2174/011570159x465328260703100233 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Review Peer reviewed
Topics	Depression Esketamine
Key findings	Reviews evidence that intranasal esketamine provides rapid antidepressant effects in treatment-resistant depression, with a need for supervised administration due to safety concerns, and discusses translational insights into its mechanisms of action.

Abstract

Esketamine in Treatment-Resistant Depression: Clinical and Translational Perspectives.

Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response. BMC Psychiatry March 17, 2026 2 citations
Esketamine and Quality of Life Improvement in Treatment-Resistant Depression Patients: A Real-World Clinical Study. J Clin Psychopharmacol November 21, 2025
A New Era for Esketamine in Managing Treatment-Resistant Depression: A Systematic Review of Its Use From Adjunct to First-Line Therapy. Cureus September 2025
Intranasal esketamine: A novel drug for treatment-resistant depression American Journal of Health-System Pharmacy August 20, 2020
Esketamine for Treatment-Resistant Depression: A Case Series and Literature Review. Cureus September 2025